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Abstract
Background: The relationship between autoantibodies against human oxidized low-density
lipoprotein (anti-oxLDL) and the progression of atherosclerotic diseases is unclear. This study
aimed to investigate the association between serum anti-oxLDL titers and the severity and
extent of coronary stenotic lesions.
Methods: We measured the titers of IgG anti-oxLDL by enzyme-linked immunosorbent assay
(ELISA) in 154 consecutive patients undergoing coronary angiography for suspected coronary
heart disease (CHD). The severity and extent of coronary stenotic lesions were evaluated on
coronary angiography findings by Gensini score.
Results: The anti-oxLDL titers were significantly lower in 117 patients with CHD than those
in 37 controls (p < 0.01). The serum anti-oxLDL titers were significantly correlated to serum
levels of globulin (r = 0.405), conjugated bilirubin (r = 0.280), high-density lipoprotein
(HDL) cholesterol (r = 0.238), homeostatic model assessment for insulin resistance (HOMA-IR)
(r = –0.267), high sensitivity C-reactive protein (hs-CRP) (r = –0.230), triglyceride
(r = –0.207), advanced glycation end products (AGEs) (r = –0.200), and malondialdehyde
(r = –0.165). However, only HDL cholesterol and AGEs remained independent predictors of
the anti-oxLDL titers after adjusting for confounders. Multivariate regression analysis showed
that the anti-oxLDL titers, as well as serum levels of hs-CRP, fasting glucose, and albumin,
were significantly associated with Gensini scores.
Conclusions: Titers of anti-oxLDL are inversely associated with complicated proatherogenic
metabolic risk factors, and the severity of coronary stenotic lesions calculated by Gensini
scores, supporting a protective role for anti-oxLDL against the progression of atherosclerosis.
(Cardiol J 2011; 18, 4: 364–370)
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Introduction
Atherosclerotic cardiovascular disease is the
commonest cause of death worldwide. A large
amount of evidence supports a pivotal role of inflam-
mation and immune responses in all phases of athe-
rosclerosis, from initiation of the fatty streak to
final breakout of acute coronary syndromes (ACS)
[1–3]. Multiple antigenic stimuli have been demon-
strated to be associated with atherogenesis [4].
Most of these stimuli come from modified self-mole-
cules such as modified low-density lipoproteins
(LDL) [5, 6], heat shock proteins [7], and protein
components of the extracellular matrix including
collagen and fibrinogen in the form of advanced gly-
cation-end products (AGEs) [8], of which oxidized
LDL (oxLDL) is the most important one [5]. Au-
toantibodies against human oxLDL (anti-oxLDL)
occur in the plasma of humans in small amounts [9].
Both IgM and IgG anti-oxLDLs are produced dur-
ing atherosclerosis. The potential roles of these
autoantibodies, especially IgG autoantibodies, in
atherogenesis remain unclear. Results from Sa-
lonen et al. [10] and Inoue et al. [11] indicate that
anti-oxLDL is an independent predictor of the pro-
gression of carotid or coronary atherosclerotic le-
sions. But immunization of atherosclerosis-suscep-
tible animals with LDL, modified LDL, or apoB100
induced high levels of the autoantibodies with de-
creased atherosclerosis, suggesting that the humo-
ral immune response to oxLDL may be antiathero-
genic [12–16].
The aim of the present study was to determine
whether anti-oxLDL titers are associated with se-
rum metabolic parameters, and whether the titers
are associated with the severity and extent of coro-




Between September 2008 and August 2009,
154 consecutive subjects were selected from pa-
tients referred to the Second Hospital of Tianjin
Medical University and undergoing coronary an-
giography because of chest pain and/or clinically
suspected coronary heart disease (CHD). Exclusion
criteria were refusal to participate, exposure to
hypolipidemic drugs in the month prior to admis-
sion, previous percutaneous coronary intervention
(PCI) or coronary artery bypass grafting (CABG),
complication of active infection, hepatic and/or re-
nal dysfunction, or connective tissue disease. The
study was approved by an institutional review com-
mittee. One hundred and seventeen subjects who
had at least one significant lesion (e.g. stenosis
≥ 50% in luminal diameter) in a major coronary
artery were diagnosed with CHD; 37 patients who
had no significant lesion in any epicardial branch of
coronary arteries proven by coronary angiography
served as control subjects.
Patient age, gender, smoking habits, past his-
tory of hypertension and diabetes, and current medi-
cations were carefully ascertained. Body mass in-
dex (BMI) was calculated as weight/height2 (kg/m2).
Laboratory measurements
Peripheral venous blood samples were drawn
from each patient after overnight fasting. Serum
levels of fasting glucose, insulin, total cholesterol,
high-density lipoprotein (HDL) cholesterol, LDL
cholesterol, triglycerides, malondialdehyde (MDA),
blood urea nitrogen (BUN), creatinine, uric acid
(UA), bilirubin, albumin, globulin, and high-sensi-
tivity C-reactive protein (hs-CRP) were measured
using conventional methods. Insulin resistance was
quantified using the homeostasis model assessment
(HOMA-IR): fasting glucose × fasting insulin level/
/22.5 [17]. Serum AGEs were measured by competi-
tive enzyme-linked immunosorbent assay (ELISA)
as previously described [18]. IgG anti-oxLDL was
assayed with a commercially available ELISA kit
(Anti-oxLDL Antibody ELISA KIT, IMTEC Diagnos-
tic Inc) as previously described [19]. Sera were di-
luted 1:101, and low- and high-titer samples were
included in each assay. Furthermore, a standard
curve with samples at known anti-oxLDL titers was
determined for each assay. All measurements were
blinded and done on coded serum samples.
Assessment of coronary stenosis
by coronary angiography
Gensini score [20] was calculated for each pa-
tient according to coronary angiography results.
The score was computed by assigning a severity
score to each coronary stenosis according to the
degree of luminal narrowing and its geographic
importance. Reduction in the lumen diameter, and
the roentgenographic appearance of concentric le-
sions and eccentric plaques were evaluated (reduc-
tions of 25%, 50%, 75%, 90%, 99%, and complete
occlusion, were given Gensini scores of 1, 2, 4, 8,
16, and 32, respectively). Each principal vascular
segment was assigned a multiplier in accordance
with the functional significance of the myocardial
area supplied by that segment: the left main coro-
nary artery × 5; the proximal segment of left ante-
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rior descending coronary artery (LAD) × 2.5; the
proximal segment of the circumflex artery × 2.5;
the mid-segment of the LAD × 1.5; the right coronary
artery, the distal segment of the LAD, the postero-
lateral artery, and the obtuse marginal artery × 1;
and others × 0.5.
Statistical analysis
Clinical data and anti-oxLDL values of controls
without CHD were compared to those of patients
with CHD using independent-sample t test or non-
-parametric Mann-Whitney test as appropriate.
Kruskal-Wallis test was used to compare anti-oxLDL
titers among controls, patients with angina pecto-
ris (AP), and patients with acute myocardial infarc-
tion (AMI). To analyze the correlations of anti-
-oxLDL titers to other variables, we used Pearson
correlation test (for serum globulin, conjugated bi-
lirubin, HDL cholesterol, hs-CRP) and nonparamet-
ric Spearman correlation test (for triglyceride,
AGEs, HOMA-IR, and MDA) as appropriate.
A multiple linear stepwise regression model was
used to analyze the predictors of anti-oxLDL titers.
To analyze the value of Gensini score, log transforma-
tion [Ln(Gensini score +1)] was firstly performed.
The association between Gensini score and other
variables was demonstrated by a linear stepwise re-
gression analysis. A p < 0.05 was considered sta-
tistically significant.
Results
Baseline characteristics of the study population are
presented in Table 1. The serum levels of anti-oxLDL
and globulin were significantly lower in patients with
CHD than those in controls (p < 0.001). In contrast,
serum levels of hs-CRP, MDA, fasting glucose, and
smoker ratio were significantly higher in patients
with CHD. Anti-oxLDL titers tended to be lower
in patients with AMI than those with AP [23.96
(18.04–28.00) vs 19.34 (16.41–26.78) U/mL, Mann-
-Whitney test, p = 0.084], but the difference was of
no statistical significance, as shown by Figure 1.
Using Pearson and nonparametric Spearman
correlation tests for all collected variables, it was
found that in all subjects anti-oxLDL titers were
Table 1. Demographic and clinical characteristics of control subjects and patients with coronary heart
disease.
Variables Controls (n = 37) CHD group (n = 117) P
Age (years) 62.0 ± 11.5 63.7 ± 10.6 0.475*
Male 24 (64.9%) 73 (63.4%) 0.681#
Hypertension 26 (70.3%) 75 (64.1%) 0.279#
Diabetes 6 (16.2%) 29 (24.8%) 0.247#
Smoker 9 (24.3%) 51 (43.6%) 0.027#
Body mass index [kg/m2] 24.6 ± 3.0 25.0 ± 3.2 0.683*
hs-CRP [mg/L] 3.03 (1.70–5.34) 8.9 (6.30–10.30) < 0.001#
Triglyceride [mmol/L] 1.43 (1.05–1.84) 1.34 (1.00–1.930) 0.800*
HDL cholesterol [mmol/L] 1.30 ± 0.20 1.21 ± 0.30 0.447*
LDL cholesterol [mmol/L] 3.00 ± 0.90 2.86 ± 0.80 0.424*
Malondialdehyde [µmmol/L] 5.21 (4.36–6.99) 6.61 (5.00–9.35) 0.005#
Anti-oxLDL titers [U/mL] 27.2 (21.9–31.3) 21.2 (16.7–27.0) 0.001#
Fasting glucose [mmol/L] 5.79 (5.06–6.17) 6.47 (5.77–8.29) < 0.001#
HOMA-IR 3.4 (2.5–5.1) 4.3 (2.92–5.3) 0.350#
AGEs [pg/mL] 41.4 (28.7–56.0) 47.9 (37.5–59.4) 0.115#
Serum albumin [g/L] 39.2 ± 2.7 37.7 ± 3.0 0.004#
Serum globulin [g/L] 29.2 ± 7.5 26.4 ± 4.1 0.005#
Conjugated bilirubin [µmmol/L] 2.9 (2.0–3.5) 2.9 (2.0–3.7) 0.563#
Blood urea nitrogen [mmol/L] 5.0 ± 1.2 5.6 ± 1.3 0.008#
Creatinine [µmmol/L] 78.1 (61.8–87.5) 79.1 (65.3–94.8) 0.479#
Uric acid [mmol/L] 315.6 (251.0–357.0) 313.0 (246.0–363.0) 0.956#
Gensini score 3.5 (2.5–5.4) 53.5 (26.0–80.5) < 0.001#
*Independent-samples t test; #nonparametric Mann-Whitney test; CHD — coronary heart disease; hs-CRP — high-sensitivity C-reactive protein;
HDL — high-density lipoprotein; LDL — low-density lipoprotein; anti-oxLDL — autoantibodies against human oxidized LDL; HOMA-IR — homeostatic
model assessment of insulin resistance; AGEs — advanced glycation-end products
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significantly correlated to levels of globulin, conju-
gated bilirubin, HDL cholesterol, hs-CRP, trigly-
cerides, HOMA-IR, AGEs, and MDA (Table 2), but
not to age, smoking status, BMI, fasting glucose,
LDL cholesterol, BUN, creatinine, UA, unconjugat-
ed bilirubin or albumin. Importantly, after adjusting
for these confounders, only AGEs (B = –0.16,
p = 0.03) and HDL cholesterol (B = 11.62, p = 0.03)
were demonstrated to be independently associat-
ed with anti-oxLDL titers in a multiple linear step-
wise regression analysis.
Then the Gensini scoring system was intro-
duced to evaluate the severity and extent of coro-
nary stenotic lesions. Using univariate stepwise lin-
ear regression analysis for all collected variables,
we demonstrated that Gensini scores were signifi-
cantly associated with hs-CRP, fasting glucose, anti-
oxLDL (Fig. 2), BUN, albumin, MDA, and globulin,
as shown by Table 3. Of these variables, anti-oxLDL
titers, serum albumin and globulin were nega-
tively associated with Gensini scores, whereas the
others were positively associated with the scores
in all subjects. After adjusting for these confound-
ers by a multiple linear stepwise regression analy-
sis, hs-CRP, fasting glucose, anti-oxLDL titers, and
serum albumin remained independently associated
with Gensini scores (Table 3).
Discussion
Innate and adaptive immune responses against
oxLDL are believed to play important roles in athe-
rosclerosis [21, 22], although reports on the clini-
cal significance of anti-oxLDL are still inconsistent.
In the conventional view, the antigen-antibody re-
Figure 1. Box-plots representing the distribution of se-
rum autoantibodies against human oxidized low-densi-
ty lipoprotein (anti-oxLDL) titers in control, angina pec-
toris (AP), and acute myocardial infarction (AMI) sub-
jects; Kruskal-Wallis test, p = 0.002; Mann-Whitney
tests established significant differences of anti-oxLDL
titers between controls and patients with AP (p =
= 0.018), and between controls and patients with AMI
(p = 0.001), but no significant differences between pa-
tients with AP and those with AMI (p = 0.084).
Table 2. Variables significantly correlated to anti-
-oxLDL titers in all subjects (n = 154).
Variables Correlation P
coefficient
Serum globulin [g/L] 0.405 < 0.001*
Conjugated bilirubin [µmmol/L] 0.280 0.001*
HDL cholesterol [mmol/L] 0.238 0.004*
HOMA-IR –0.267 0.018#
hs-CRP [mg/L] –0.230 0.005*
Triglyceride [mmol/L] –0.207 0.011#
AGEs [pg/mL] –0.200 0.029#
Malondialdehyde [µmmol/L] –0.165 0.042#
*Pearson correlation test; #nonparametric Spearman correlation test;
anti-oxLDL — autoantibodies against human oxidized low-density
lipoprotein; hs-CRP — high-sensitivity C-reactive protein; HDL —
high-density lipoprotein; HOMA-IR — homeostatic model assessment
of insulin resistance; AGEs — advanced glycation end products
Figure 2. Correlation of serum autoantibodies against
human oxidized low-density lipoprotein (anti-oxLDL) ti-
ters to Gensini scores in all subjects (n = 154); Spearman
correlation analysis showed a negative correlation betwe-
en serum anti-oxLDL titers and Gensini score [Ln(Gensini
score +1)] in all subjects; R = –0.306, p < 0.001.
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action is prone to enhance inflammation and results
in exacerbation of atherosclerosis. Reports on ele-
vated anti-oxLDL titers in humans with increased
carotid atherosclerosis [10] and CHD [11] suggest
a proatherogenic role for the autoantibodies. How-
ever, Rossi et al. [23] found that there was no dif-
ference of anti-oxLDL titers between patients with
and without ACS. The method they used to evalu-
ate the severity of coronary lesions was to count
the diseased vessels, which is prone to neglect the
difference between severe lesions such as total
occlusion and moderate stenosis, or the difference
between multiple plaques and just one plaque in one
coronary artery. Their study found a tendency for
patients with multiple vessels disease to have low-
er anti-oxLDL titers, but the differences were not
statistically significant. Similarly to our data, San-
tos et al. [24] recently reported that anti-oxLDL
titers were higher, whereas levels of hs-CRP were
lower in hypertensive patients than in individuals
who experienced a recent ACS. However, coronary
angiography was not used in their study, meaning
the conditions of diseased coronary arteries were
unknown. In the present study, we introduced the
Gensini scoring system to evaluate the extent and
severity of coronary stenotic lesions, because the
coronary trees in this system are divided into
15 segments and even mild lesions (e.g. less than
25% stenosis in diameter) are also calculated in the
final score. Therefore our data enriched the previ-
ous findings: the titers of anti-oxLDL are negatively
associated with the severity and extent of coronary
stenotic lesions.
Recently, increasing evidence has supported
the protective role of the autoantibodies and humo-
ral immunity against modified LDL. Evidence from
innate natural antibodies, represented by the pro-
totypic antibody E06, has shown the ability of the
antibodies to bind to oxidized phospholipids (PL) of
oxLDL, and inhibit the uptake of oxLDL by mac-
rophage scavenger receptors, thus inhibiting the
development of foam cells [25]. Furthermore, im-
munization of atherosclerosis-prone mice directly
with modified or native LDL [12, 14, 15], or with
the protein part of modified LDL [13, 16], exerts
a protective effect on lesion formation, supporting
the involvement of adaptive immune response in
atherogenesis and its protective roles. More intere-
stingly, it has been demonstrated that passive im-
munization with polyclonal immunoglobulin prepa-
rations [26], monoclonal anti-phosphorylcholine
IgM antibody [27] or recombinant human antibod-
ies against aldehyde-modified apolipoprotein B-100
peptide sequences [28, 29] significantly inhibited
atherosclerosis and dose-dependently reduced the
extent of atherosclerosis, as well as the plaque con-
tent of oxLDL epitopes and macrophages. Recent
results from an oxLDL-pulsed mature dendric cells-
-transferred study demonstrated that a reduced
T helper cell-1 profile and an increment in oxLDL-
-specific IgG levels contributed to a reduction in
foam cell formation [30]. The relationship between
Gensini scores and the titers of anti-oxLDL in our
study also suggested that anti-oxLDL may confer
a protective role against the progression of athero-
sclerosis, although the role is weak.
Table 3. Linear regression analysis of factors associated with Gensini score (n = 154)*.
B 95% CI for B P
Univariate stepwise:
hs-CRP [mg/L] 0.182 0.131–0.234 < 0.001
Fasting glucose [mmol/L] 0.168 0.092–0.244 < 0.001
Anti-oxLDL titers [U/mL] –0.031 –0.047–0.016 < 0.001
Blood urea nitrogen [mmol/L] 0.250 0.108–0.392 0.001
Malondialdehyde [µmmol/L] 0.054 0.019–0.089 0.003
Serum albumin [g/L] –0.096 –0.159–0.032 0.003
Serum globulin [g/L] –0.055 –0.091–0.018 0.003
Multivariate stepwise#:
hs-CRP [mg/L] 0.144 0.093–0.195 < 0.001
Fasting glucose [mmol/L] 0.125 0.058–0.193 < 0.001
Anti-oxLDL titers [U/mL] –0.020 –0.033–0.006 0.006
Serum albumin [g/L] –0.060 –0.114–0.005 0.033
*Dependent variable is Gensini score [Ln(Gensini score +1)]; #in multiple linear stepwise regression, induced variables are age, hs-CRP, fasting glu-
cose, anti-oxLDL titers, serum albumin, serum globulin, blood urea nitrogen, malondialdehyde; CI — confidence interval; hs-CRP — high-sensitivity
C-reactive protein; anti-oxLDL — autoantibodies against human oxidized low-density lipoprotein
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In the present study, anti-oxLDL titers were
correlated to multiple metabolic and inflammatory
risk factors, including HDL cholesterol, hs-CRP,
triglycerides, HOMA-IR, AGEs, and MDA. But only
AGEs and HDL were independent predictors of the
anti-oxLDL titers after adjusting for these con-
founders: AGEs levels were negatively associated
with anti-oxLDL titers; whereas HDL levels were
positively associated with anti-oxLDL titers. It has
been shown that anti-oxLDL titers are selectively
higher in a good metabolic homeostasis. Kara et al.
[31] demonstrated that anti-oxLDL levels were in-
versely correlated to hemoglobin A1c (HbA1c) le-
vels in children with diabetes, and when metabolic
control worsened, the free anti-oxLDL levels de-
creased concurrently. Garrido-Sánchez et al. [32]
also reported that the levels of IgG and IgM anti-
oxLDL in morbidly obese patients rose after bari-
atric surgery, but this increase was only significant
in the diabetic patient who experienced an improve-
ment in their metabolic profile. AGEs are modifi-
cations of proteins or lipids that become nonenzy-
matically glycated and oxidized after contact with
aldose sugars [33]. The AGEs accumulation is not
just a measure of hyperglycemia, but represents
cumulative metabolic burden, oxidative stress and
inflammation [34]. Low HDL-C level is an impor-
tant cardiovascular risk factor. HDL not only has
a central role in the reverse transport of cholesterol,
but also has anti-oxidative and anti-inflammatory
properties [35]. Therefore our data suggests that
low anti-oxLDL titer might reflect a complicated
proatherogenic metabolic profile, including both
glucose and lipid metabolic disorders.
It is well-known that serum CRP level is an
independent predictor of CHD, especially the un-
stable coronary plaques, and its prognostic value
exceeds that of LDL cholesterol [36–38]. CRP in
vitro has been shown to be able to bind both oxLDL
[39], and native LDL [40] to opsonize their intake
by macrophages, thus resulting in the formation of
foam cells. In our study, anti-oxLDL titers were
negatively associated with Gensini scores, where-
as CRP remained positively associated with the
scores, suggesting a possible opposite role of anti-
-oxLDL on atherogenesis against CRP.
Interestingly, we found that serum albumin
was also an independent predictor of Gensini
scores. This agrees with a previous study of pa-
tients with chronic kidney disease, in which serum
albumin level was shown to be independently as-
sociated with multivessel CHD and Gensini scores
by stepwise regression analysis [41]. An early study
in patients without chronic kidney disease also
showed that serum albumin had an independent
negative association with the angiographic severi-
ty of CHD [42]. We presumed that coexistent renal
lesions, including endothelial dysfunction and pro-
gression of atherosclerosis, may be possible under-
lying mechanisms, as seen in the review of Schif-
frin et al. [43].
Conclusions
In conclusion, our data showed that titers of
anti-oxLDL were inversely associated with compli-
cated proatherogenic metabolic risk factors, and the
severity of coronary stenotic lesions calculated by
Gensini scores. The results suggest that anti-oxLDL
may play a protective role against the progression
of atherosclerosis. However, this assumption should
be treated with caution, because it was based on
a relatively small number of subjects and represen-
ted a phenomenon occurring at a single time of
atherogenesis.
Limitations of the study
Our data was only based on coronary angio-
graphy findings, by which less stenotic plaques may
not be detected. Therefore, this result did not include
all atherosclerotic lesions in coronary arteries.
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